Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines
Journal of Thrombosis and Haemostasis · 2024
DOI: 10.1016/j.jtha.2024.08.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Hendy Kristyanto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Vaccines & Prevention B.V., Leiden, The Netherlands. Hauptthemen laut MEDLINE: Platelet Factor 4, COVID-19 Vaccines, Vaccination, Ad26COVS1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BARDA.
Abstract (Originalsprache)
BACKGROUND: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse event identified following vaccination with some adenovirus-vectored COVID-19 vaccines, including Ad26.COV2.S. VITT is characterized by the presence of antibodies against platelet factor 4 (PF4). OBJECTIVES: To evaluate whether PF4 antibodies were generally induced following vaccination with adenovirus type 26 (Ad26)-vectored vaccines. METHODS: The study included 913 and 991 healthy participants without thromboembolic (TE) events in Ad26.COV2.S and non-COVID-19 Ad26-vectored vaccine clinical studies, respectively, and 1 participant with VITT following Ad26.COV2.S vaccination. PF4 antibody levels were measured in prevaccination and postvaccination sera. PF4 antibody positivity rates were assessed in a case-control setting in participants who developed TE events during participation in Ad26-vectored vaccine clinical studies. RESULTS: In the 1 VITT patient, PF4 antibodies were negative before vaccination. Seroconversion for platelet-activating PF4 antibodies was observed upon Ad26.COV2.S vaccination. In participants without TE events, the PF4 antibody levels and positivity rates were similar before and after Ad26 vaccination. Ad26 vaccination did not increase PF4 antibody levels in participants who were PF4 antibody-positive at baseline (n = 47). Lastly, 1 out of 28 TE cases and 2 out of 156 non-TE controls seroconverted after Ad26.COV2.S vaccination. None of the 15 TE cases and 3 of the 77 non-TE controls seroconverted following non-COVID-19 Ad26 vaccination. CONCLUSION: Ad26.COV2.S and the other Ad26-vectored vaccines studied did not generally induce PF4 antibodies or increase preexisting PF4 antibody levels. Moreover, unlike VITT, TE events that occurred at any time following Ad26 vaccination were not associated with PF4 antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
- Janssen Research & Development, Beerse, Belgium.
- Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
- Janssen Vaccines & Prevention B.V., Leiden, The Netherlands. Electronic address: JHendri1@its.jnj.com.
Förderung
- BARDA
Zitieren
APA
Kristyanto, H., Slaets, L., Braams, E., Scheys, I., Heesbeen, R., Cárdenas, V., Shukarev, G., Scheper, G., Sadoff, J., Lühn, K., Schuitemaker, H., Struyf, F., & Hendriks, J. (2024). Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.08.019
Vancouver
Kristyanto H, Slaets L, Braams E, Scheys I, Heesbeen R, Cárdenas V, et al. Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.08.019
BibTeX
@article{Kristyanto2024,
author = {Kristyanto, Hendy and Slaets, Leen and Braams, Esmée and Scheys, Ilse and Heesbeen, Roy and Cárdenas, Vicky and Shukarev, Georgi and Scheper, Gert and Sadoff, Jerald and Lühn, Kerstin and Schuitemaker, Hanneke and Struyf, Frank and Hendriks, Jenny},
title = {Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26–vectored vaccines},
journal = {Journal of Thrombosis and Haemostasis},
year = {2024},
doi = {10.1016/j.jtha.2024.08.019}
}
EUVIMED